Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a tablet Eye-Tracker replace the Neurologist's exam for MS?

NCT ID NCT06256731

Diagnosis Sponsor: Innodem Neurosciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether a tablet-based eye-tracking device (ETNA-MS) can accurately estimate disability levels in people with Multiple Sclerosis. Sixty adults with MS took eye-tracking tests, and the device's estimates were compared to standard neurologist assessments. The goal is to see if this simple, quick test can reliably monitor disease progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Eye-tracking device (ETNA-MS)
What this could lead to
If successful, this device could offer a quick, objective way to monitor MS disability without needing a full in-person neurologist exam.
What could go wrong
This is a small, completed validation study with 60 people. The device may not be accurate enough for all patients or settings, and it only estimates disability, not treat it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

60 people

The number who actually took part.

Started

Dec 2023

Finished

Jun 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Our target sample size for the MS group is 60. Eligible patients with MS will be selected and categorized based on their EDSS score.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to provide informed consent * Aged 18 years or older at the time of enrolment * Able to read in either English, Spanish or French * Able to read the oculomotor task on-screen instructions at the testing distance (45 cm) with or without corrective lenses * Confirmed diagnosis of MS as per the Macdonald criteria, irrespective of MS subtype (relapsing-remitting (RRMS), secondary-progressive (SPMS), primary-progressive (PPMS), and progressive-relapsing (PRMS)) * Neurologist-determined EDSS score between 1.0-4.5 Exclusion Criteria: * Evidence or medical history of a neuropsychiatric disorder such as schizophrenia and autism, which are known to impair eye movements and oculomotor control. * Presence of comorbid neurological conditions causing significant eye movement anomalies (such as strabismus, cranial nerve palsy, stroke-causing hemianopsia). * Diagnosis of macular edema or other pre-existing ocular conditions that would prevent a participant from performing the eye movement assessments. * Having started a new prescription medication or having changed the dose of a medication known to influence ocular motor visual function (e.g. benzodiazepines, antipsychotics, and anticonvulsants) within the past three months. * Participants with non-disease related physical impairments to a leg, hand, or arm (e.g., broken bone or severe sprain) that would not allow completion of the assessments. * Having an EDSS score for which the desired sample size has been reached.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis

Contacts and locations

Locations

  • MS Integrated Center

    Phoenix, Arizona, 85018, United States

  • Memorial Healthcare

    Owosso, Michigan, 48867, United States

  • Michigan Institute for Neurological Disorders

    Farmington Hills, Michigan, 48334, United States

  • Premier Neurology Research, P.C.

    Greenville, South Carolina, 29605, United States

  • Rocky Mountain MS Research Group

    Salt Lake City, Utah, 84103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.